Soo RA, Huat Tan E, Hayashi H, Seto T, et al. Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial. Lung Cancer 2022;169:67-76.
PMID: 35660971